$AMWLBearishLow

Gotlib Phyllis sold $35K of AMWL

Gotlib Phyllis (President, International) sold 3,573 shares of American Well Corp (AMWL) at $9.74 on 2026-06-01.

6/10
6/10
Low
Bearish
Filed 2026-06-03; sale dated 2026-06-01.
Slightly negative—insider selling can pressure sentiment, but magnitude is small.

Insider selling is a modest negative signal, but this specific Form 4 (open-market, no 10b5-1 plan stated) is unlikely to be a standalone catalyst.

AMWL President, International Gotlib Phyllis sold 3,573 shares in an open-market transaction disclosed via SEC Form 4.

Low near-term impact; any reaction is likely limited to sentiment/positioning rather than fundamentals.

Background

This is an SEC Form 4 insider transaction disclosure for American Well Corp (AMWL).

Why it matters

The disclosure updates insider-trading sentiment for AMWL but does not include any new operational or financial catalyst.

Market relevance

Traders may treat the sale as a mild negative sentiment input, but the dollar value is relatively small and not a fundamental trigger.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Alternative perspectives

A small open-market sale can be routine liquidity management and may not reflect a bearish view of AMWL fundamentals.

The filing notes no pre-arranged 10b5-1 plan, but it still lacks context (taxes, diversification, planned expenses) that often explains insider sales.

Key entities

  • American Well Corp

    Subject of the SEC Form 4 insider sale by an officer.

  • Gotlib Phyllis

    President, International who sold 3,573 shares of AMWL on 2026-06-01.

Related articles

$AMWLMed

[8-K] American Well Corp Reports Material Event

American Well Corporation (AMWL) reported its first-quarter 2026 results, showing shrinking losses despite a year-over-year revenue decline. The company achieved $54.9 million in revenue, a net loss of $10.3 million, and an adjusted EBITDA loss of $3.1 million. Amwell reaffirmed its full-year 2026 revenue guidance and updated its adjusted EBITDA outlook, maintaining its target for positive cash flow from operations in Q4 2026.

$AMWLMed

Amwell (NYSE: AMWL) slashes 2025 loss and issues cautious 2026 guidance

Amwell Corporation (NYSE: AMWL) reported significant improvements in its 2025 financial results, sharply reducing its net loss to $95.0 million from $212.6 million in 2024 and improving Adjusted EBITDA to $(39.9) million from $(134.4) million. Despite the strong performance in 2025, the company issued cautious guidance for 2026, forecasting lower revenue of $195-$205 million, but projecting continued improvement in Adjusted EBITDA to $(24)-$(18) million, with the goal of achieving positive cash flow from operations by Q4 2026. The company's strategic shift towards a leaner, more efficient model, focusing on its Technology Enabled Care platform, is highlighted as key to its transformation and future sustainability.